| Mustafa Amjad Akbiek, MD | |
|
311 9th St N Ste 310, Naples, FL 34102-5889 | |
| (239) 624-8250 | |
| (239) 624-8251 |
| Full Name | Mustafa Amjad Akbiek |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 13 Years |
| Location | 311 9th St N Ste 310, Naples, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679989115 | NPI | - | NPPES |
| ZVPAG | Other | FL | BCBS |
| 101954900 | Medicaid | FL | |
| ME132036 | Other | FL | LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | ME132036 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Naples Community Hospital | Naples, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nchmd Inc | 9436139565 | 374 |
News Archive
Genzyme Corporation announced today that it will reopen enrollment in the Alglucosidase Alfa Temporary Access Program (ATAP), a program which provides access to treatment for severely affected adults with Pompe disease prior to commercial approval of Lumizyme™ (alglucosidase alfa). Genzyme and the FDA have also agreed on a path toward approval of Lumizyme.
Autism researchers at the University of Pennsylvania School of Nursing have found a link between low birthweight and children diagnosed with autism, reporting premature infants are five times more likely to have autism than children born at normal weight.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942.
For medical devices, as with many medicines, the market for children is a small fraction of the adult market, and there are far fewer child-sized devices. But, of course, the need exists, even if proper devices may not.
› Verified 1 days ago
| Entity Name | Nchmd Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831120195 PECOS PAC ID: 9436139565 Enrollment ID: O20040721000254 |
News Archive
Genzyme Corporation announced today that it will reopen enrollment in the Alglucosidase Alfa Temporary Access Program (ATAP), a program which provides access to treatment for severely affected adults with Pompe disease prior to commercial approval of Lumizyme™ (alglucosidase alfa). Genzyme and the FDA have also agreed on a path toward approval of Lumizyme.
Autism researchers at the University of Pennsylvania School of Nursing have found a link between low birthweight and children diagnosed with autism, reporting premature infants are five times more likely to have autism than children born at normal weight.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942.
For medical devices, as with many medicines, the market for children is a small fraction of the adult market, and there are far fewer child-sized devices. But, of course, the need exists, even if proper devices may not.
› Verified 1 days ago
| Entity Name | Millennium Physician Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811122880 PECOS PAC ID: 9830244433 Enrollment ID: O20090903000338 |
News Archive
Genzyme Corporation announced today that it will reopen enrollment in the Alglucosidase Alfa Temporary Access Program (ATAP), a program which provides access to treatment for severely affected adults with Pompe disease prior to commercial approval of Lumizyme™ (alglucosidase alfa). Genzyme and the FDA have also agreed on a path toward approval of Lumizyme.
Autism researchers at the University of Pennsylvania School of Nursing have found a link between low birthweight and children diagnosed with autism, reporting premature infants are five times more likely to have autism than children born at normal weight.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942.
For medical devices, as with many medicines, the market for children is a small fraction of the adult market, and there are far fewer child-sized devices. But, of course, the need exists, even if proper devices may not.
› Verified 1 days ago
| Entity Name | Premier Inpatient Partners Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568916492 PECOS PAC ID: 3476832528 Enrollment ID: O20161114002121 |
News Archive
Genzyme Corporation announced today that it will reopen enrollment in the Alglucosidase Alfa Temporary Access Program (ATAP), a program which provides access to treatment for severely affected adults with Pompe disease prior to commercial approval of Lumizyme™ (alglucosidase alfa). Genzyme and the FDA have also agreed on a path toward approval of Lumizyme.
Autism researchers at the University of Pennsylvania School of Nursing have found a link between low birthweight and children diagnosed with autism, reporting premature infants are five times more likely to have autism than children born at normal weight.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942.
For medical devices, as with many medicines, the market for children is a small fraction of the adult market, and there are far fewer child-sized devices. But, of course, the need exists, even if proper devices may not.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mustafa Amjad Akbiek, MD Po Box 26067, Salt Lake City, UT 84126-0067 Ph: (239) 624-0400 | Mustafa Amjad Akbiek, MD 311 9th St N Ste 310, Naples, FL 34102-5889 Ph: (239) 624-8250 |
News Archive
Genzyme Corporation announced today that it will reopen enrollment in the Alglucosidase Alfa Temporary Access Program (ATAP), a program which provides access to treatment for severely affected adults with Pompe disease prior to commercial approval of Lumizyme™ (alglucosidase alfa). Genzyme and the FDA have also agreed on a path toward approval of Lumizyme.
Autism researchers at the University of Pennsylvania School of Nursing have found a link between low birthweight and children diagnosed with autism, reporting premature infants are five times more likely to have autism than children born at normal weight.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942.
For medical devices, as with many medicines, the market for children is a small fraction of the adult market, and there are far fewer child-sized devices. But, of course, the need exists, even if proper devices may not.
› Verified 1 days ago
Ricardo Martinez, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 851 5th Ave N Ste 102, Naples, FL 34102 Phone: 239-315-7801 Fax: 855-888-3291 | |
Dr. Karen Moss Ezrine, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 762 Regency Reserve Cir, Naples, FL 34119 Phone: 239-354-1998 | |
Dr. Lawrence Kenneth Harris, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 2171 Pine Ridge Rd, Suite F, Naples, FL 34109 Phone: 239-566-7425 Fax: 239-593-3430 | |
Todd David Brodie, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 730 Goodlette Rd N, Ste 205, Naples, FL 34102 Phone: 239-436-3666 Fax: 239-436-3678 | |
Dr. Frank Michael Elterman, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6101 Pine Ridge Rd, Naples, FL 34119 Phone: 239-330-2933 Fax: 855-691-0391 | |
Vincent Charles Bianca Iii, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 9015 Strada Stell Ct, Suite 201, Naples, FL 34109 Phone: 239-597-5638 Fax: 239-597-5628 | |
Catherine Nina Kowal, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1855 Veterans Park Dr, Suite 103, Naples, FL 34109 Phone: 239-596-5220 Fax: 239-643-9816 |